Methods for treating scleroderma by administering a soluble CTLA4 molecule
US9296808B2 · kind B2 · utility
5Cited by
55References
1Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Feb 28, 2014 |
| Grant date | Mar 29, 2016 |
| Priority date | — |
| Expiry date | Jun 21, 2034 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC07K2319/00
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
The present invention relates to compositions and methods for treating autoimmune diseases, such as scleroderma, by administering to a subject a CTLA4 molecule that block endogenous B7 molecules from binding their ligands.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.